<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Immunizations in patients with inborn errors of immunity
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Immunizations in patients with inborn errors of immunity
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Immunizations in patients with inborn errors of immunity
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Craig D Platt, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Luigi D Notarangelo, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna M Feldweg, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 13, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1798556607">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infections in patients with inborn errors of immunity (IEI; formerly "primary immunodeficiency disorders"), often result in excessive morbidity and mortality, and antimicrobial therapy may be less effective than in the unimpaired host. Therefore, prevention through vaccination is an important component of care for patients with these diseases [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         This topic review will discuss immunizations in patients with IEI. Other measures to prevent infection in this patient population include
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         therapy, prophylactic antimicrobials, and lifestyle modifications, which are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/3948.html" rel="external">
          "Inborn errors of immunity (primary immunodeficiencies): Overview of management"
         </a>
         .)
        </p>
        <p>
         Topics on vaccination of patients with various forms of secondary immunodeficiency are found separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3899.html" rel="external">
          "Immunizations in adults with cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3706.html" rel="external">
          "Immunizations in persons with HIV"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1963.html" rel="external">
          "Immunizations in patients with end-stage kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3891.html" rel="external">
          "Immunizations for adults with chronic liver disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">
          "Prevention of infection in patients with impaired splenic function", section on 'Vaccinations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3882.html" rel="external">
          "Immunizations in hematopoietic cell transplant candidates and recipients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">
          "Immunizations in solid organ transplant candidates and recipients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2671592696">
         <span class="h1">
          APPROACH TO THE PATIENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two questions should always be considered before vaccinating a patient with an IEI:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Could the patient be harmed by administration of a live viral or bacterial vaccine? In some IEI, infectious agents in live vaccines can proliferate and cause disseminated infection and vaccine-induced disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Will the patient make a sufficient response to the vaccine to justify its use?
        </p>
        <p>
        </p>
        <p>
         The approach presented in this topic review is consistent with recommendations from the United States Centers for Disease Control and Prevention (CDC) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2931678764">
         <span class="h2">
          Safety
         </span>
         <span class="headingEndMark">
          —
         </span>
         During vaccine development, tests of safety and efficacy are performed on immunologically normal individuals, so safety in immunodeficient patients must be estimated based on the immune defect present.
        </p>
        <p>
         Adverse events associated with vaccines should be reported to the United States Department of Health and Human Services using the Vaccine Adverse Events Reporting System (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaers.hhs.gov%2Findex.html&amp;token=8m3rK0tzv73hmwLVujPJP%2FVrZTr5LmKIlDf%2BMKp07YKCkZawMmw76Mlq0N%2Fh3R%2BM&amp;TOPIC_ID=106521" target="_blank">
          VAERS
         </a>
         ; telephone number 1-800-822-7967). Reportable events are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/3884.html" rel="external">
          "Standard immunizations for nonpregnant adults", section on 'Adverse event reporting'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2876.html" rel="external">
          "Standard immunizations for children and adolescents: Overview", section on 'Reporting adverse events'
         </a>
         .)
        </p>
        <p>
         The United States government Vaccine Injury Compensation Program (VICP), established in 1988, compensates patients, including immunodeficient infants, children, and adults, who are thought to have suffered death or other injury as a result of administration of a childhood vaccine. Full details are available elsewhere on the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hrsa.gov%2Fvaccine-compensation&amp;token=u%2FUXY8mj4f2cUyB56IXs7qOolfzCxrVuGbGqM1v8arZ%2F2pGiQGidEyjwsarwXsBYVTgfTLyl4JJiuXh5Ckq0Mg%3D%3D&amp;TOPIC_ID=106521" target="_blank">
          Health Resources and Services Administration website
         </a>
         [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4272325300">
         <span class="h3">
          Killed, inactivated, mRNA, or subcomponent vaccines
         </span>
         <span class="headingEndMark">
          —
         </span>
         Killed or subcomponent vaccines may contain inactivated whole, fragmented, or modified bacteria and viruses, as well as toxoids, purified polysaccharides, and protein-polysaccharide conjugate vaccines. The messenger ribonucleic acid (mRNA) vaccines in use against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be considered to be subcomponent vaccines as well. These types of vaccines have no risk beyond what is encountered in immunocompetent individuals and may be given to immunodeficient patients when they offer possible benefit [
         <a href="#rid4">
          4-6
         </a>
         ]. Among those vaccines that are unlikely to be harmful, some are of particular importance to patients with certain IEI because they are at increased risk for these infections, such as pneumococcal and meningococcal vaccines in patients with complement deficiencies  (
         <a class="graphic graphic_table graphicRef110756" href="/z/d/graphic/110756.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2035156881">
         <span class="h3">
          Live vaccines
         </span>
         <span class="headingEndMark">
          —
         </span>
         The safety of live (also called live-attenuated) vaccines varies with the degree of immunodeficiency. Particularly in patients with combined immunodeficiencies (but also in other rare instances discussed below), vaccination with live vaccines can cause disseminated infection. Vaccine-induced infection in patients with unrecognized immunodeficiency has been reported with oral polio vaccine [
         <a href="#rid7">
          7-10
         </a>
         ], rotavirus [
         <a href="#rid11">
          11-13
         </a>
         ], Bacille Calmette-Guérin (BCG) [
         <a href="#rid14">
          14
         </a>
         ], varicella vaccines [
         <a href="#rid15">
          15,16
         </a>
         ], and with measles from the measles-mumps-rubella (MMR) vaccine [
         <a href="#rid17">
          17-19
         </a>
         ]. Beginning in 2000, oral polio vaccines were no longer licensed in the United States and Canada, although they are still used in other parts of the world.
        </p>
        <p>
         In countries that are implementing newborn screening for severe combined immunodeficiency (SCID) disorders, the vast majority of affected infants will be detected before any live vaccines are given. Infants with a positive screening test should not be given any live vaccines until SCID and other conditions involving T cell lymphopenia have been excluded. The principal exception to this generalization occurs in countries where
         <a class="drug drug_general" data-topicid="102736" href="/z/d/drug information/102736.html" rel="external">
          BCG vaccine
         </a>
         is routinely administered before discharge from the hospital, which may occur before the results of newborn screening are available in some cases. In contrast, in countries without newborn screening programs, inadvertent administration to a newborn with an IEI remains a risk.
         <a class="drug drug_general" data-topicid="10273" href="/z/d/drug information/10273.html" rel="external">
          Rotavirus vaccines
         </a>
         should not be given to infants in the hospital or the nursery, because of possible spread to severely immunocompromised patients. (See
         <a class="medical medical_review" href="/z/d/html/16363.html" rel="external">
          "Newborn screening for inborn errors of immunity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2926379556">
         <span class="h4">
          Viral
         </span>
         <span class="headingEndMark">
          —
         </span>
         Live viral vaccines include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MMR (see
         <a class="medical medical_review" href="/z/d/html/101273.html" rel="external">
          "Measles, mumps, and rubella immunization in infants, children, and adolescents"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Measles-mumps-rubella-varicella
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral poliovirus (not available in the United States) (see
         <a class="medical medical_review" href="/z/d/html/2695.html" rel="external">
          "Poliovirus vaccination", section on 'Live attenuated oral poliovirus vaccine'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Live-attenuated influenza vaccine (see
         <a class="medical medical_review" href="/z/d/html/5960.html" rel="external">
          "Seasonal influenza in children: Prevention with vaccines"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Yellow fever (see
         <a class="medical medical_review" href="/z/d/html/3890.html" rel="external">
          "Immunizations for travel", section on 'Yellow fever vaccine'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Varicella (see
         <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">
          "Vaccination for the prevention of chickenpox (primary varicella infection)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Herpes zoster (no longer available in the United States) (see
         <a class="medical medical_review" href="/z/d/html/8343.html" rel="external">
          "Vaccination for the prevention of shingles (herpes zoster)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rotavirus (see
         <a class="medical medical_review" href="/z/d/html/6023.html" rel="external">
          "Rotavirus vaccines for infants"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Smallpox (vaccinia)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adenovirus (used predominantly in military personnel)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2640368511">
         <span class="h4">
          Bacterial
         </span>
         <span class="headingEndMark">
          —
         </span>
         Live bacterial vaccines include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         BCG (see
         <a class="medical medical_review" href="/z/d/html/8022.html" rel="external">
          "Prevention of tuberculosis: BCG immunization and nutritional supplementation"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral Ty21a
         <em>
          Salmonella typhimurium
         </em>
         (see
         <a class="medical medical_review" href="/z/d/html/3890.html" rel="external">
          "Immunizations for travel", section on 'Typhoid vaccine'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H373893193">
         <span class="h2">
          Efficacy of vaccination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with specific disorders may not respond fully to vaccines, although the general advice is to vaccinate if there is possible benefit to the patient. The greater the degree of immunosuppression, the less likely the patient is to generate protective immunity.
        </p>
        <p class="headingAnchor" id="H844056716">
         <span class="h1">
          RISK ACCORDING TO TYPE OF IEI
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with IEI can receive inactivated vaccines according to the routine schedule (provided the patient has the theoretical ability to respond to vaccines). The use of
         <strong>
          live attenuated
         </strong>
         vaccines is discussed in this section.
        </p>
        <p class="headingAnchor" id="H1591434581">
         <span class="h2">
          Combined immunodeficiencies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with combined immunodeficiencies have impaired cellular (T cell) and humoral (B cell) immunity. All live vaccines (viral and bacterial) are contraindicated in severe and partial combined immunodeficiencies  (
         <a class="graphic graphic_table graphicRef110756" href="/z/d/graphic/110756.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe IEI include severe combined immunodeficiency (SCID) and complete DiGeorge syndrome (DGS). All live vaccines of any type are contraindicated in these disorders. Inactivated vaccines are unlikely to be effective and are not typically administered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Partial combined immunodeficiencies include Wiskott-Aldrich syndrome (WAS), ataxia-telangiectasia, and many others. All live vaccines are generally contraindicated in these disorders. Inactivated vaccines may be at least partially effective in some cases and can be administered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vaccination in less severe DGS (most patients) is considered on a case-by-case basis. Those patients with &gt;500 CD3+ T lymphocytes/mm
         <sup>
          3
         </sup>
         , &gt;200 CD8+ T lymphocytes, and normal proliferative response to mitogens can be considered for measles-mumps-rubella (MMR) and varicella vaccination. Measles-mumps-rubella-varicella is contraindicated [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H47349983">
         <span class="h2">
          Antibody deficiencies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some live viral and bacterial vaccines are contraindicated in antibody deficiencies, depending upon the severity of antibody dysfunction  (
         <a class="graphic graphic_table graphicRef110756" href="/z/d/graphic/110756.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H568005525">
         <span class="h3">
          Severe
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe IEI affecting B cell function (ie, humoral immunity) include X-linked (or autosomal recessive) agammaglobulinemia and common variable immunodeficiency. These patients should not receive certain live vaccines, such as oral poliovirus, smallpox, live-attenuated influenza vaccine, yellow fever, or live oral typhoid vaccines. Other live vaccines, such as MMR or varicella, are not given, because patients on
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         therapy should have passive immunization.
        </p>
        <p class="headingAnchor" id="H4044528355">
         <span class="h3">
          Mild
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with milder antibody deficiencies, such as symptomatic immunoglobulin A (IgA) or immunoglobulin G (IgG) subclass deficiencies or specific antibody deficiency, should not receive the oral poliovirus, Bacille Calmette-Guérin (BCG), or yellow fever vaccines but can receive other live vaccines if they are not receiving IgG replacement [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3011622911">
         <span class="h2">
          Phagocyte defects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Phagocyte defects include congenital neutropenias, chronic granulomatous disease (CGD), leukocyte-adhesion deficiency, and myeloperoxidase deficiency. Patients with these disorders should not be given live
         <strong>
          bacterial
         </strong>
         vaccines  (
         <a class="graphic graphic_table graphicRef110756" href="/z/d/graphic/110756.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. However, all can safely receive live viral vaccines with the exception of those with leukocyte-adhesion defects and cytotoxic granule defects, who may have some deficiency in viral responses as well [
         <a href="#rid5">
          5,21-23
         </a>
         ].
        </p>
        <p>
         Influenza vaccine is strongly recommended for CGD as influenza infection has an important association with severe secondary bacterial infections in these patients [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3563127697">
         <span class="h2">
          Complement deficiencies and congenital asplenia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with complement deficiencies have intact cellular and humoral immunity and can receive all live and inactivated vaccines. It is especially important to vaccinate these patients against
         <em>
          Neisseria meningitidis
         </em>
         ,
         <em>
          Streptococcus pneumoniae
         </em>
         , and
         <em>
          Haemophilus influenzae
         </em>
         . Similarly, patients with congenital asplenia should be immunized against these encapsulated bacteria using protein-conjugated vaccines. (See
         <a class="local">
          'Vaccines recommended for specific IEI'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2929073279">
         <span class="h2">
          Innate immune defects
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with defects in innate immunity, the specific susceptibilities seen with each disorder should guide vaccine use. Examples are given below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with innate immune defects that are associated with invasive bacterial infections should not be given live bacterial vaccines, such as the
         <em>
          Salmonella
         </em>
         vaccine. Examples of these disorders include defects in the interleukin (IL) 12-interferon (IFN) gamma axis, nuclear factor-kappa-B essential modulator (NEMO) deficiency, and GATA-binding protein 2 (GATA2) deficiency. (See
         <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">
          "Mendelian susceptibility to mycobacterial diseases: Specific defects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with innate immune defects associated with severe viral infections (eg, defects in type 1 interferon signaling, such as signal transducer and activator of transcription 1 deficiency and signal transducer and activator of transcription 2 deficiency) should not receive live viral vaccines [
         <a href="#rid25">
          25,26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">
          "Mendelian susceptibility to mycobacterial diseases: Specific defects", section on 'STAT1 defects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who have increased susceptibility to mycobacterial infections (all the disorders mentioned above) should not be given the
         <a class="drug drug_general" data-topicid="102736" href="/z/d/drug information/102736.html" rel="external">
          BCG vaccine
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">
          "Mendelian susceptibility to mycobacterial diseases: Specific defects", section on 'STAT1 defects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All live viral and bacterial vaccines are contraindicated in disorders of the nuclear factor-kappa-B pathway that present as a combined immunodeficiency. (See
         <a class="medical medical_review" href="/z/d/html/3951.html" rel="external">
          "Syndromic immunodeficiencies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2493516899">
         <span class="h2">
          Phenocopies of IEI
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term "phenocopy" refers to an acquired somatic mutation or autoimmune process resulting in a phenotype that mimics an inherited germline mutation. A category called "phenocopies of inborn errors of immunity" includes disorders caused by somatic mutations in genes, as well as disorders caused by autoantibodies to various cytokines, cell surface glycoproteins, or complement factors. The presence of autoantibodies to cytokines can result in immunodeficiency states similar to those caused by inherited defects in the affected pathways. Infections associated with these disorders are variable, as with defects of innate immunity, and similar considerations apply. For example, patients with autoantibodies to IFN-gamma are similar to those with Mendelian susceptibility to mycobacterial disease and should not receive live bacterial vaccines (BCG or
         <em>
          Salmonella
         </em>
         vaccine). Those with autoantibodies to type 1 interferons should not receive live viral vaccines [
         <a href="#rid27">
          27-29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/89801.html" rel="external">
          "Mendelian susceptibility to mycobacterial diseases: An overview", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3325607590">
         <span class="h1">
          VACCINES RECOMMENDED FOR SPECIFIC IEI
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vaccines that are particularly important for patients with different types of IEI and secondary immunodeficiency states because of underlying susceptibilities are reviewed in the table  (
         <a class="graphic graphic_table graphicRef110756" href="/z/d/graphic/110756.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H83273575">
         <span class="h2">
          Inactivated influenza
         </span>
         <span class="headingEndMark">
          —
         </span>
         A yearly
         <a class="drug drug_general" data-topicid="9055" href="/z/d/drug information/9055.html" rel="external">
          inactivated influenza vaccine
         </a>
         is recommended for all patients with IEI who are capable of responding to vaccination in any capacity. This is especially important for some IEI, such as chronic granulomatous disease (CGD).
        </p>
        <p>
         Some patients may respond better to repeated doses or higher doses (ie, two standard doses at least one month apart or high-dose vaccine).
        </p>
        <p class="headingAnchor" id="H2544234708">
         <span class="h2">
          Pneumococcal vaccine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pneumococcal vaccination with the conjugate vaccine is recommended for patients with combined immunodeficiencies, antibody deficiency, complement deficiencies, congenital asplenia, and phagocyte disorders who are not receiving
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (
         <a class="graphic graphic_table graphicRef110756" href="/z/d/graphic/110756.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. In addition, patients with interleukin (IL) 1-receptor-associated kinase 4 (IRAK4) deficiency or myeloid differentiation primary response gene 88 (MyD88) deficiency are particularly susceptible to invasive pneumococcal disease and should be vaccinated.
        </p>
        <p>
         During the course of evaluation for humoral immunodeficiency, patients with milder antibody deficiencies, such as symptomatic IgA or IgG subclass deficiencies or specific antibody deficiency, are frequently vaccinated with the
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          pneumococcal polysaccharide vaccine
         </a>
         (PPV23) after two years of age for purpose of assessing responsiveness to polysaccharide antigens (ie, as part of the diagnosis). Patients who are complete nonresponders are often treated with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         . However, partial responders may derive some protection as a result of vaccination.
        </p>
        <p class="headingAnchor" id="H196828133">
         <span class="h2">
          Meningococcal vaccine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Meningococcal vaccine should be administered to patients with complement defects, congenital asplenia, and those with combined immunodeficiencies. For patients with asplenia, conjugated meningococcal vaccines are recommended as patients may not respond to the pure polysaccharide vaccine. The different conjugated vaccines for prevention of meningococcal infection are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/3901.html" rel="external">
          "Meningococcal vaccination in children and adults", section on 'MenACWY'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H471789622">
         <span class="h2">
          <i>
           Haemophilus influenzae
          </i>
          b vaccine
         </span>
         <span class="headingEndMark">
          —
         </span>
         One dose of
         <em>
          H. influenzae
         </em>
         type b (Hib) conjugate vaccine should be given after five years of age to unimmunized patients at increased risk for infections with encapsulated bacteria [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1202287643">
         <span class="h2">
          Human papilloma virus vaccine
         </span>
         <span class="headingEndMark">
          —
         </span>
         The human papilloma virus vaccine should be considered for all patients but especially for those with increased susceptibility to papilloma virus infection, including ataxia-telangiectasia, CD40/CD40 ligand deficiency, common variable immunodeficiency, dedicator of cytokinesis 8 (DOCK8) deficiency, epidermodysplasia verruciformis, GATA-binding protein 2 (GATA2) deficiency, idiopathic CD4 lymphopenia, leukocyte-adhesion deficiency type 1, nuclear factor-kappa-B essential modulator (NEMO) deficiency, Netherton syndrome, serine threonine kinase 4 (STK4) deficiency, WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, WILD (warts, immunodeficiency, lymphedema, and anogenital dysplasia) syndrome, or Wiskott-Aldrich syndrome (WAS) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2846580977">
         <span class="h2">
          Zoster vaccine
         </span>
         <span class="headingEndMark">
          —
         </span>
         The recombinant zoster (shingles) vaccine (Shingrix [brand name]) is a non-live subunit vaccine for use in adults over the age of 50 years and for patients 18 years or older with immunodeficiency conditions that increase the risk of varicella-zoster virus (VZV) infection. This includes patients with combined immunodeficiencies and natural killer (NK) deficiency but also a growing number of disparate IEI that share susceptibility to VZV and other herpes viruses [
         <a href="#rid30">
          30
         </a>
         ]. The vaccine is normally given as two doses separated by two to six months, but, in immunodeficient patients, the second dose can be given one to two months after the first. (See
         <a class="medical medical_review" href="/z/d/html/8343.html" rel="external">
          "Vaccination for the prevention of shingles (herpes zoster)"
         </a>
         .)
        </p>
        <p>
         Note that vaccination against VZV is not needed in patients receiving regular infusions of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         . (See
         <a class="local">
          'Passive protection'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1882671843">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3232941351">
         <span class="h2">
          Patients receiving immune globulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several issues to consider in patients with IEI who are receiving
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         .
        </p>
        <p class="headingAnchor" id="H1722858803">
         <span class="h3">
          Passive protection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients receiving regular infusions of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         should have protective titers to most common vaccine agents (eg, measles-mumps-rubella-varicella) given to the general population and are at least partly protected from these diseases. Immune globulin contains protective titers of antibodies to pneumococcus and
         <em>
          H. influenza
         </em>
         type B (Hib) and variable (but usually protective) titers to meningococcus [
         <a href="#rid31">
          31-33
         </a>
         ]. In contrast, immune globulin contains low levels of antibodies to circulating pathogenic strains of influenza because antigenic drift and shift with influenza are sufficient to prevent the formation of herd immunity, necessitating yearly immunization [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Immunodeficient patients on maintenance
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         who are exposed to an illness for which a "hyperimmune" immune globulin is recommended (eg, rabies, hepatitis B, tetanus) should receive the pathogen-specific immune globulin in the recommended dose since standard immune globulin preparations have no or variable levels of antibodies to these pathogens.
        </p>
        <p class="headingAnchor" id="H2305339403">
         <span class="h3">
          Interference with vaccine response
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the presence of neutralizing antibodies against the organisms in common vaccines in
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         provides protection against infection, these same antibodies may render live-attenuated vaccines inactive. Thus, most experts do not administer routine vaccines to patients receiving immune globulin, except against those pathogens to which there is little antibody in the plasma donor pool (eg, influenza) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Interference by
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         on vaccine response has been documented for measles, rubella, and varicella live vaccines, while the effect on mumps vaccine is not known [
         <a href="#rid20">
          20,34,35
         </a>
         ]. If desired and appropriate based on the underlying diagnosis, these vaccines could be given once the patient has stopped immune globulin for a period of 3 to 11 months, depending upon the immune globulin dose. Other live vaccines that are not given routinely to the general population may be given to patients receiving immune globulin, provided they are considered safe for that patient.
        </p>
        <p class="headingAnchor" id="H2808119844">
         <span class="h2">
          Healthy household contacts of immunodeficient patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         All inactivated vaccines should be offered to healthy household contacts (HHCs) of immunocompromised patients, according to the usual schedule.
        </p>
        <p>
         Recommendations about live viral vaccines are as follows and apply to HHCs of immunocompromised individuals who cannot receive live viral vaccines themselves [
         <a href="#rid36">
          36
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HHCs should be given the vaccines for varicella, measles-mumps-rubella (MMR), and rotavirus [
         <a href="#rid5">
          5,20,37
         </a>
         ]. MMR and varicella viruses are not significantly shed from the immunized individual after these vaccines. However, if the HHC develops a rash after
         <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">
          varicella vaccine
         </a>
         , the immunocompromised patient should be isolated from that contact, and zoster
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         should be administered to the immunocompromised individual. Immunocompromised patients should not handle diapers of infants who have been vaccinated with rotavirus vaccine for four weeks after vaccination [
         <a href="#rid5">
          5,37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9055" href="/z/d/drug information/9055.html" rel="external">
          Inactivated influenza vaccine
         </a>
         is recommended for HHCs (in preference to live influenza vaccine).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HHCs should
         <strong>
          not
         </strong>
         be given oral polio vaccine, because of the possibility of fecal-oral transmission.
         <a class="drug drug_general" data-topicid="10175" href="/z/d/drug information/10175.html" rel="external">
          Smallpox vaccine
         </a>
         is also contraindicated [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other live viral and bacterial vaccines, aside from those discussed above (ie, oral polio, live influenza, and smallpox), can be safely given to HHCs because there is no evidence of increased risk of transmission of infection to immunocompromised contacts.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H988826676">
         <span class="h2">
          Patients with IEI undergoing hematopoietic cell transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recommendations for vaccination of patients with IEI following hematopoietic cell transplantation are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/3882.html" rel="external">
          "Immunizations in hematopoietic cell transplant candidates and recipients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4285431829">
         <span class="h2">
          Infants and children with hypogammaglobulinemia of infancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         If otherwise well, these infants should receive the recommended doses of killed vaccines at the appropriate ages. Premature infants in the nursery should not receive oral rotavirus vaccine until the date of discharge, because of possible spread through the nursery. Older infants with transient hypogammaglobulinemia can also receive routine killed vaccines. Hypogammaglobulinemic infants beyond one year of age should be studied for an IEI before live virus vaccines are given.
        </p>
        <p class="headingAnchor" id="H4125552628">
         <span class="h2">
          Pregnant people at risk for having an immunodeficient child
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnant people are routinely vaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) and
         <a class="drug drug_general" data-topicid="9055" href="/z/d/drug information/9055.html" rel="external">
          inactivated influenza vaccine
         </a>
         . However, if a pregnant person is at risk for having a child with immunodeficiency, they should also receive pneumococcal, Hib, and meningococcal vaccines. This is recommended to generate protective maternal IgG antibodies that will be transferred to the newborn and provide protection in the first few months after birth [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H114501181">
         <span class="h2">
          Vaccinations for travel
         </span>
         <span class="headingEndMark">
          —
         </span>
         Issues related to vaccination and travel in immunocompromised individuals are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3890.html" rel="external">
          "Immunizations for travel", section on 'Immunocompromised patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3896.html" rel="external">
          "Travel advice for immunocompromised hosts"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3741496458">
         <span class="h1">
          ISSUES RELATED TO SARS-COV-2 VACCINATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Three vaccines have been authorized by the US Food and Drug Administration (FDA) for prevention of coronavirus disease 2019 (COVID-19) in the United States (see
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines"
         </a>
         ). Two of these vaccines are composed of lipid nanoparticle-enclosed RNA that encodes the spike (S) protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus (Pfizer and Moderna). A third vaccine (Novavax) is a protein subunit vaccine. As of May 2023, the
         <a class="drug drug_general" data-topicid="130461" href="/z/d/drug information/130461.html" rel="external">
          Janssen/Johnson &amp; Johnson COVID-19 vaccine
         </a>
         (Ad26.COV2.S) is no longer available in the United States. All three vaccines are considered inactivated or subcomponent vaccines. They have no risk beyond what is encountered in immunocompetent individuals and may be given to immunodeficient patients when they offer possible benefit.
        </p>
        <p>
         No significant adverse events have been reported in any study examining SARS-CoV-2 immunizations in patients with IEI.
        </p>
        <p>
         Data on immune responses to COVID-19 vaccines in patients with IEI are generally encouraging [
         <a href="#rid38">
          38,39
         </a>
         ]. With the exception of X-linked agammaglobulinemia and combined immunodeficiencies, most patients with IEI generate protective antibody responses. Notably, antigen-specific T cell responses have been detected in patients with X-linked agammaglobulinemia, suggesting a degree of T cell-mediated protection even in patients who are not able to make an antibody response [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         The US Centers for Disease Control and Prevention (CDC) have been making recommendations regarding vaccination for patients with "moderate to severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)" [
         <a href="#rid40">
          40
         </a>
         ]. Given this guidance, patients and clinicians may question whether specific diagnoses are classified as "moderate to severe." It is important to note that IEI are typically not classified by severity, and, for most disorders, little is known about the specific susceptibility to COVID-19 or the durability of the vaccine response. We therefore advise clinicians to consider their patients based on their diagnosis and an assessment of immune function, as well as their risk for acquiring COVID-19 infection in their community. We feel that any patient with an IEI diagnosis should be considered to have a moderate-to-severe immunodeficiency for the purpose of these guidelines. Guidance from organizations focused on specific disorders may be available as an additional resource. Recommendations for immunocompromised patients, including those with IEI, are described in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines", section on 'Immunocompromised individuals'
         </a>
         .)
        </p>
        <p>
         We do not obtain antibody levels following vaccination. Patients and clinicians may wish to assess vaccine response after the vaccination series is complete by measuring levels of antibodies against the S protein. However, there are several issues that complicate interpretation of such testing:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Protective antibody levels have not been identified for the general population.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antibody testing does not assess the efficacy of T cell responses, which are also relevant to a protective immune response.
        </p>
        <p>
        </p>
        <p>
         There are data that suggest that
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         may offer some protection from COVID-19 as immune globulin preparations now contain neutralizing anti-SARS-CoV-2 antibodies [
         <a href="#rid41">
          41-43
         </a>
         ]. Vaccination remains necessary as there are no data on clinical efficacy of immune globulin at reducing in SARS-CoV-2 infections or infection severity.
        </p>
        <p class="headingAnchor" id="H277766837">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112831.html" rel="external">
          "Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1249620876">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Safety and efficacy
         </strong>
         – Two questions should be asked when considering immunization in a patient with an inborn error of immunity (IEI; formerly "primary immunodeficiency disorder"): Is the specific vaccine safe for this patient, and is it likely to be effective? (See
         <a class="local">
          'Approach to the patient'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vaccines containing killed microorganisms, messenger ribonucleic acid (mRNA) encoding proteins, or subcomponents of microorganisms are safe for all immunocompromised patients and should be given if the patient has sufficient ability to generate an immune response. In contrast, vaccines containing live-attenuated viruses or bacteria may result in unchecked proliferation and disseminated disease and are contraindicated in many forms of IEI  (
         <a class="graphic graphic_table graphicRef110756" href="/z/d/graphic/110756.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Safety'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with specific disorders may not respond fully to vaccines, although the general advice is to vaccinate if there is possible benefit to the patient. (See
         <a class="local">
          'Efficacy of vaccination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Issues related to
         </strong>
         <strong>
          immune globulin
         </strong>
         –
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          Immune globulin
         </a>
         contains antibodies to common vaccine agents (eg, measles, varicella) and should provide at least partial protection from these diseases in patients who receive regular treatments. Important exceptions are influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) given that titers in immune globulin may not be specific for the circulating strains of these viruses. Immune globulin can also reduce the efficacy of some vaccines. (See
         <a class="local">
          'Patients receiving immune globulin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Some vaccines are important for specific IEI
         </strong>
         – Certain vaccines are specifically recommended for patients with different types of IEI and secondary immunodeficiency states because of underlying susceptibilities  (
         <a class="graphic graphic_table graphicRef110756" href="/z/d/graphic/110756.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Vaccines recommended for specific IEI'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1148558910">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Francisco A Bonilla, MD, PhD, and E Richard Stiehm, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sobh A, Bonilla FA. Vaccination in Primary Immunodeficiency Disorders. J Allergy Clin Immunol Pract 2016; 4:1066.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 14th ed, Hall E, Wodi AP, Hamborsky J, et al (Eds). Public Health Foundation, 2021. http://www.cdc.gov/vaccines/pubs/pinkbook/index.html (Accessed on August 01, 2023).
         </li>
         <li class="breakAll">
          Health Resources and Services Administration. National Vaccine Injury Compensation Program. https://www.hrsa.gov/vaccine-compensation/index.html (Accessed on July 30, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol 2015; 136:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonilla FA. Update: Vaccines in primary immunodeficiency. J Allergy Clin Immunol 2018; 141:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hidalgo S, García Erro M, Cisterna D, Freire MC. Paralytic poliomyelitis caused by a vaccine-derived polio virus in an antibody-deficient Argentinean child. Pediatr Infect Dis J 2003; 22:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gumede N, Muthambi V, Schoub BD. Immunodeficiency-associated vaccine-derived poliovirus type 3 in infant, South Africa, 2011. Emerg Infect Dis 2012; 18:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander JP, Ehresmann K, Seward J, et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis 2009; 199:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaghaghi M, Parvaneh N, Ostad-Rahimi P, et al. Combined immunodeficiency presenting with vaccine-associated paralytic poliomyelitis: a case report and narrative review of literature. Immunol Invest 2014; 43:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakare N, Menschik D, Tiernan R, et al. Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). Vaccine 2010; 28:6609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010; 362:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Werther RL, Crawford NW, Boniface K, et al. Rotavirus vaccine induced diarrhea in a child with severe combined immune deficiency. J Allergy Clin Immunol 2009; 124:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeganeh M, Heidarzade M, Pourpak Z, et al. Severe combined immunodeficiency: a cohort of 40 patients. Pediatr Allergy Immunol 2008; 19:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghaffar F, Carrick K, Rogers BB, et al. Disseminated infection with varicella-zoster virus vaccine strain presenting as hepatitis in a child with adenosine deaminase deficiency. Pediatr Infect Dis J 2000; 19:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy O, Orange JS, Hibberd P, et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis 2003; 188:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bitnun A, Shannon P, Durward A, et al. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 1999; 29:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neven B, Pérot P, Bruneau J, et al. Cutaneous and Visceral Chronic Granulomatous Disease Triggered by a Rubella Virus Vaccine Strain in Children With Primary Immunodeficiencies. Clin Infect Dis 2017; 64:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perelygina L, Icenogle J, Sullivan KE. Rubella virus-associated chronic inflammation in primary immunodeficiency diseases. Curr Opin Allergy Clin Immunol 2020; 20:574.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Immunization and other considerations in immunocompromised children. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.72.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohl S, Springer TA, Schmalstieg FC, et al. Defective natural killer cytotoxicity and polymorphonuclear leukocyte antibody-dependent cellular cytotoxicity in patients with LFA-1/OKM-1 deficiency. J Immunol 1984; 133:2972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anikeeva N, Somersalo K, Sims TN, et al. Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 2005; 102:6437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrews T, Sullivan KE. Infections in patients with inherited defects in phagocytic function. Clin Microbiol Rev 2003; 16:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finelli L, Fiore A, Dhara R, et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics 2008; 122:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dupuis S, Jouanguy E, Al-Hajjar S, et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet 2003; 33:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bucciol G, Moens L, Ogishi M, et al. Human inherited complete STAT2 deficiency underlies inflammatory viral diseases. J Clin Invest 2023; 133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dai YS, Liang MG, Gellis SE, et al. Characteristics of mycobacterial infection in patients with immunodeficiency and nuclear factor-kappaB essential modulator mutation, with or without ectodermal dysplasia. J Am Acad Dermatol 2004; 51:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42:1473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bastard P, Michailidis E, Hoffmann HH, et al. Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J Exp Med 2021; 218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ansari R, Rosen LB, Lisco A, et al. Primary and Acquired Immunodeficiencies Associated With Severe Varicella-Zoster Virus Infections. Clin Infect Dis 2021; 73:e2705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chua I, Lagos M, Charalambous BM, et al. Pathogen-specific IgG antibody levels in immunodeficient patients receiving immunoglobulin replacement do not provide additional benefit to therapeutic management over total serum IgG. J Allergy Clin Immunol 2011; 127:1410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adam E, Church JA. Antibody levels to Bordetella pertussis and Neisseria meningitidis in immunodeficient patients receiving immunoglobulin replacement therapy. J Clin Immunol 2015; 35:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldacker S, Draeger R, Warnatz K, et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol 2007; 124:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siber GR, Werner BG, Halsey NA, et al. Interference of immune globulin with measles and rubella immunization. J Pediatr 1993; 122:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arciuolo RJ, Jablonski RR, Zucker JR, Rosen JB. Effectiveness of Measles Vaccination and Immune Globulin Post-Exposure Prophylaxis in an Outbreak Setting-New York City, 2013. Clin Infect Dis 2017; 65:1843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medical Advisory Committee of the Immune Deficiency Foundation, Shearer WT, Fleisher TA, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol 2014; 133:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delmonte OM, Castagnoli R, Notarangelo LD. COVID-19 and Inborn Errors of Immunity. Physiology (Bethesda) 2022; 37:0.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Leeuwen LPM, GeurtsvanKessel CH, Ellerbroek PM, et al. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity. J Allergy Clin Immunol 2022; 149:1949.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention (CDC). COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html (Accessed on August 01, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romero C, Díez JM, Gajardo R. Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products-an update. Lancet Infect Dis 2022; 22:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Volk A, Covini-Souris C, Kuehnel D, et al. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin. BioDrugs 2022; 36:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Upasani V, Townsend K, Wu MY, et al. Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein. Clin Infect Dis 2023; 77:950.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 106521 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27836056" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Vaccination in Primary Immunodeficiency Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27836056" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Vaccination in Primary Immunodeficiency Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27836056" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Vaccination in Primary Immunodeficiency Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26371839" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Practice parameter for the diagnosis and management of primary immunodeficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24311479" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29288077" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Update: Vaccines in primary immunodeficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12828159" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Paralytic poliomyelitis caused by a vaccine-derived polio virus in an antibody-deficient Argentinean child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22607733" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Immunodeficiency-associated vaccine-derived poliovirus type 3 in infant, South Africa, 2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19090774" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24294834" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Combined immunodeficiency presenting with vaccine-associated paralytic poliomyelitis: a case report and narrative review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20674876" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20107217" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Vaccine-acquired rotavirus in infants with severe combined immunodeficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19660805" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Rotavirus vaccine induced diarrhea in a child with severe combined immune deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18093084" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Severe combined immunodeficiency: a cohort of 40 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10959752" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Disseminated infection with varicella-zoster virus vaccine strain presenting as hepatitis in a child with adenosine deaminase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14513412" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10589903" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Measles inclusion-body encephalitis caused by the vaccine strain of measles virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27810866" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Cutaneous and Visceral Chronic Granulomatous Disease Triggered by a Rubella Virus Vaccine Strain in Children With Primary Immunodeficiencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33044342" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Rubella virus-associated chronic inflammation in primary immunodeficiency diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33044342" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Rubella virus-associated chronic inflammation in primary immunodeficiency diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6092461" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Defective natural killer cytotoxicity and polymorphonuclear leukocyte antibody-dependent cellular cytotoxicity in patients with LFA-1/OKM-1 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15851656" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14557288" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Infections in patients with inherited defects in phagocytic function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18829805" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12590259" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36976641" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Human inherited complete STAT2 deficiency underlies inflammatory viral diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15523349" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Characteristics of mycobacterial infection in patients with immunodeficiency and nuclear factor-kappaB essential modulator mutation, with or without ectodermal dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35748970" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33544838" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32856043" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Primary and Acquired Immunodeficiencies Associated With Severe Varicella-Zoster Virus Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21376379" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Pathogen-specific IgG antibody levels in immunodeficient patients receiving immunoglobulin replacement do not provide additional benefit to therapeutic management over total serum IgG.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25631528" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Antibody levels to Bordetella pertussis and Neisseria meningitidis in immunodeficient patients receiving immunoglobulin replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17602874" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Active vaccination in patients with common variable immunodeficiency (CVID).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8429432" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Interference of immune globulin with measles and rubella immunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29028959" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effectiveness of Measles Vaccination and Immune Globulin Post-Exposure Prophylaxis in an Outbreak Setting-New York City, 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24582311" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21293327" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35944006" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : COVID-19 and Inborn Errors of Immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35421449" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35421449" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34953544" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products-an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34843105" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37338118" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
